Company News: T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer
T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, today announced the appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer. Elisa Kieback, T-knife’s co-founder and founding CEO, has assumed the role of Chief Technical Officer.
Allero Therapeutics Expands Management Team with Two Key Hires
Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, today announced the appointment of two key members to its management team.
As of December 1, 2020, Steven Glazer has joined the Company as Chief Medical Officer and Christophe Saillez as Vice President Regulatory Affairs.
Company News: First-In-Human Heart Failure Data of Cardior Pharmaceuticals´ Novel miRNA Antisense Therapy Presented at the 17th Global Cardiovascular Clinical Trialists Forum
— Excellent safety and tolerability of first-in-class compound CDR132L
— Novel mode of action confirmed by data on cardiac function and biomarkers
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, today announced that its Chief Scientific Officer Thomas Thum, MD, PhD, has presented clinical data on the Company´s lead compound CDR131L at the 17th Global Cardiovascular Clinical Trialists Forum (CVCT) on December 7, 2020.
